Latest News about ENTA
Recent news which mentions ENTA
From MarketWatch
From Benzinga
From Benzinga
From Benzinga
Enanta Pharmaceuticals Shares Fall After RSVP Phase 2b study results Miss Primary Endpoint
May 18, 2022
Tickers
ENTA
From Benzinga
10 Biggest Price Target Changes For Tuesday
May 10, 2022
From Benzinga
Tickers
ENTA
From Motley Fool
Enanta Pharma Commences Dosing In Phase 1 COVID-19 Trial
February 16, 2022
Tickers
ENTA
From Benzinga
Enanta Pharmaceuticals (ENTA) Q1 2022 Earnings Call Transcript
February 09, 2022
Tickers
ENTA
From Motley Fool
Earnings Scheduled For February 8, 2022
February 08, 2022
From Benzinga
What 10 Analyst Ratings Have To Say About Enanta Pharmaceuticals
January 13, 2022
Tickers
ENTA
From Benzinga
10 Biggest Price Target Changes For Thursday
January 13, 2022
From Benzinga
7 A-Rated Biotechs to Buy for the Long Run
December 03, 2021
From InvestorPlace
56 Biggest Movers From Yesterday
November 24, 2021
From Benzinga
Enanta Pharmaceuticals, inc (ENTA) Q4 2021 Earnings Call Transcript
November 22, 2021
Tickers
ENTA
From Motley Fool
52 Biggest Movers From Friday
November 22, 2021
From Benzinga
Earnings Scheduled For November 22, 2021
November 22, 2021
From Benzinga
The Week Ahead In Biotech (Nov. 21-Nov. 27): Takeda, Aadi, Fennec FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week
November 21, 2021
From Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
November 19, 2021
From Benzinga
The Daily Biotech Pulse: Connect Biopharma Sinks On Eczema Drug Readout, Enanta Pulls Plug On HBV Drug, Clinical Setback For Merck In HIV Trial
November 19, 2021
From Benzinga
Safety Signals Force Enanta To Stop EDP-721 HBV Program
November 19, 2021
Tickers
ENTA
From Benzinga
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
November 08, 2021
From Benzinga
10 Biggest Price Target Changes For Monday
November 08, 2021
From Benzinga
Pfizer to seek authorization of COVID-19 pill ‘as soon as possible’
November 05, 2021
From MarketWatch